Holen Sie sich die Stockscreener-App
2.59
0.38%
-0.01
Handel nachbörslich:
2.52
-0.07
-2.70%
Schlusskurs vom Vortag:
$2.60
Offen:
$2.69
24-Stunden-Volumen:
61,096
Relative Volume:
0.95
Marktkapitalisierung:
$7.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.11M
KGV:
-0.2416
EPS:
-10.7181
Netto-Cashflow:
$-13.60M
1W Leistung:
+16.67%
1M Leistung:
+39.25%
6M Leistung:
-18.81%
1J Leistung:
-57.33%
1-Tages-Spanne:
$2.5312
$2.7443
1-Wochen-Bereich:
$2.15
$2.89
52-Wochen-Spanne:
$1.6701
$14.24
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Firmenname
Processa Pharmaceuticals Inc
Sektor
Branche
Telefon
443-776-3133
Adresse
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
2.59 | 7.20M | 0 | -14.11M | -13.60M | -10.72 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-25 | Eingeleitet | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Aktie (PCSA) Neueste Nachrichten
Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.605|Chg%:+0.005 - TradingKey
Processa Pharma Market Sentiment - Benzinga España
Processa Pharmaceuticals Inc (PCSA) Income Statement - TradingKey
Processa Pharmaceuticals Inc (PCSA) Balance Sheet - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.600|Chg%:-0.270 - TradingKey
Processa Pharmaceuticals Inc (PCSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Processa Pharmaceuticals Q4 2025 Earnings: EPS Miss Drives Stock Surge – Investor Focus Shifts to Pipeline - dars.gov.et
Processa Pharma (PCSA) Stock Analysis Report | Financials & Insights - Benzinga España
Insider Buying: Russell Skibsted Acquires Additional Shares of P - GuruFocus
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock - Investing.com
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock By Investing.com - Investing.com South Africa
Form 4 Processa Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
Insider purchase: Processa (NASDAQ: PCSA) CAO adds 2,436 shares in open-market buy - Stock Titan
Processa (PCSA) strategy chief adds 2,106 shares in insider buy - Stock Titan
Processa Pharmaceuticals (PCSA) CEO adds 3,057 shares in open-market buy - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Ng George K - Moomoo
CFO of Processa (NASDAQ: PCSA) adds 3,277 shares in open-market buy - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SKIBSTED RUSSELL - Moomoo
Processa Pharmaceuticals (PCSA) director buys 2,531 shares in open market - Stock Titan
Processa Pharmaceuticals, Inc. Financial Disclosures & SEC Filings - TradingView
Form 4 Processa Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Processa (NASDAQ: PCSA) director Yorke vests 203-share restricted stock award - Stock Titan
[Form 4] Processa Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Processa Pharmaceuticals (PCSA) director receives 203 shares from vesting - Stock Titan
Processa Pharmaceuticals (PCSA) director gets 203 shares from service award - Stock Titan
PCSA Q4 2025 Earnings: Wider-than-Expected Loss Highlights Clinical Stage ChallengesEarnings Turnaround - dars.gov.et
Enterprise value to EBIT forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Price to sales forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Price to book forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Price to earnings forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Enterprise value to revenue forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Processa Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PCSA) - TradingView
PCSA | Processa Pharmaceuticals, Inc. Common Executive Compensation - Quiver Quantitative
Shareholders to vote on Processa (NASDAQ: PCSA) equity plan and pay - Stock Titan
Processa Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
Processa Pharmaceuticals Inc (PCSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Processa Pharmaceuticals Inc (PCSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Processa Pharmaceuticals Inc - TradingKey
Processa Pharmaceuticals Inc (PCSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Processa Pharmaceuticals Inc (PCSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Processa Pharmaceuticals Inc (PCSA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Processa Pharmaceuticals Inc (PCSA) Institutional Confidence - TradingKey
Processa Pharmaceuticals CFO Russell Skibsted buys $5,891 in stock By Investing.com - Investing.com UK
Processa Pharmaceuticals chief business officer Lin buys $4,064 stock By Investing.com - Investing.com India
Processa Pharmaceuticals CEO George Ng buys $5,472 in stock By Investing.com - Investing.com Australia
Processa Pharmaceuticals CFO Russell Skibsted buys $5,891 in stock - Investing.com
Processa Pharmaceuticals chief business officer Lin buys $4,064 stock - Investing.com UK
Processa Pharmaceuticals CEO George Ng buys $5,472 in stock - Investing.com UK
Processa Pharma president of R&D David Young buys $4,588 in stock - Investing.com Canada
Processa Pharma president of R&D David Young buys $4,588 in stock By Investing.com - Investing.com South Africa
Finanzdaten der Processa Pharmaceuticals Inc-Aktie (PCSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):